STOCKHOLM, Sweden, Feb. 16, 2009 (GLOBE NEWSWIRE) -- Diamyd Medical has received approval from the Swedish Medical Products Agency to continue to follow the children who participated in the company's Phase II study of the Diamyd(r) diabetes vaccine, which started four years ago. The aim of the follow-up study is to confirm the vaccine's long-term effect.
